Induction of human allergen-specific immune regulation following treatment with a combination of Toll-Like Receptor 7 agonist with allergen: an in vit

点击翻译按钮获取中文摘要

Allergic rhinitis and asthma result from aberrant Th2-type immune reactivity against common inhaled allergens. Existing therapies alleviate symptomatology, but do not offer alteration of disease progress. The only therapeutic modality that has been associated with the development of immune tolerance to allergens and modification of underlying disease pathophysiology is allergen specific immunotherapy. However, allergen immunotherapy has several limitations, including the need of regular administration for several years, that restrict its effectiveness and broad application. To improve its efficacy and dosing regimen co-administration with immunopotentiators capable of promoting in a controlled fashion, the generation of Th1 and/or regulatory T and B cell responses has been proposed.